Survival benefit of transcatheter arterial chemoembolization in patients with hepatocellular carcinoma larger than 10 cm in diameter

被引:71
作者
Huang, YH
Wu, JC
Chen, SC
Chen, CH
Chiang, JH
Huo, TI
Lee, PC
Chang, FY
Lee, SD
机构
[1] Taipei Vet Gen Hosp, Dept Med Res & Educ, Taipei 112, Taiwan
[2] Taipei Vet Gen Hosp, Div Gastroenterol, Dept Med, Taipei, Taiwan
[3] Natl Yang Ming Univ, Inst Clin Med, Sch Med, Taipei 112, Taiwan
[4] Natl Yang Ming Univ, Fac Med, Sch Med, Taipei 112, Taiwan
[5] Kaohsiung Med Univ Hosp, Dept Internal Med, Hepatobiliary Div, Coll Med, Kaohsiung, Taiwan
[6] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 10764, Taiwan
[7] Natl Taiwan Univ, Coll Med, Taipei 10764, Taiwan
关键词
D O I
10.1111/j.1365-2036.2006.02704.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background The safety and survival benefit of transcatheter arterial chemoembolization for patients with huge hepatocellular carcinoma is uncertain. Aim To evaluate the role of embolization in unresectable hepatocellular carcinomas larger than 10 cm. Methods Twenty-six consecutive patients who had an unresectable hepatocellular carcinoma larger than 10 cm and refused aggressive treatment, were enrolled as the control group. Another 31 patients matching with the control cases and undergoing embolization for huge unresectable hepatocellular carcinoma served as the embolization group. Survival between the two groups was compared. Results Two patients (7%) died from embolization-related complications. Patients in embolization group had longer survival than those in control group (median survival: 9.13 vs. 2.1 months). The 1-, 3- and 5-year survival rates in embolization group were 42%, 13% and 7% respectively. The land 3-year survival rates for patients in control group were 8% and 0% respectively. In multivariate analysis, embolization and prothrombin ratio <= 1.2 were two independent factors associated with a better survival. Conclusions Embolization-related mortality is low for huge hepatocellular carcinoma, and the technique provides survival benefit in patients with unresectable hepatocellular carcinomas larger than 10 cm in diameter.
引用
收藏
页码:129 / 135
页数:7
相关论文
共 25 条
[1]   Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma:: Results of a randomized, controlled trial in a single institution [J].
Bruix, J ;
Llovet, JM ;
Castells, A ;
Montañá, X ;
Brú, C ;
Ayuso, MD ;
Vilana, R ;
Rodés, J .
HEPATOLOGY, 1998, 27 (06) :1578-1583
[2]  
COX DR, 1972, J R STAT SOC B, V34, P187
[3]   Rising incidence of hepatocellular carcinoma in the United States [J].
El-Serag, HB ;
Mason, AC .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (10) :745-750
[4]   HEPATIC RESECTION FOR A HEPATOCELLULAR-CARCINOMA LARGER THAN 10 CM [J].
FURUTA, T ;
SONODA, T ;
MATSUMATA, T ;
KANEMATSU, T ;
SUGIMACHI, K .
JOURNAL OF SURGICAL ONCOLOGY, 1992, 51 (02) :114-117
[5]   Supportive treatment, resection and transcatheter arterial chemoembolization in resectable hepatocellular carcinoma: an analysis of survival in 419 patients [J].
Huang, YH ;
Wu, JC ;
Chau, GY ;
Lui, WY ;
King, KL ;
Chiang, JH ;
Yen, SH ;
Sheng, WY ;
Hou, MC ;
Lu, CL ;
Chang, FY ;
Lee, SD .
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 1999, 11 (03) :315-321
[6]   Comparison of recurrence after hepatic resection in patients with hepatitis B vs. hepatitis C-related small hepatocellular carcinoma in hepatitis B virus endemic area [J].
Huang, YH ;
Wu, JC ;
Chen, CH ;
Chang, TT ;
Lee, PC ;
Chau, GY ;
Lui, WY ;
Chang, FY ;
Lee, SD .
LIVER INTERNATIONAL, 2005, 25 (02) :236-241
[7]   The role of transcatheter arterial embolization for patients with unresectable hepatocellular carcinoma: a nationwide, multicentre study evaluated by cancer stage [J].
Huang, YH ;
Chen, CH ;
Chang, TT ;
Chen, SC ;
Chiang, JH ;
Lee, HS ;
Lin, PW ;
Huang, GT ;
Sheu, JC ;
Tsai, HM ;
Lee, PC ;
Huo, TI ;
Lee, SD ;
Wu, JC .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2005, 21 (06) :687-694
[8]   The role of transcatheter arterial embolization in patients with resectable hepatocellular carcinoma: a nation-wide, multicenter study [J].
Huang, YH ;
Chen, CH ;
Chang, TT ;
Chen, SC ;
Wang, SY ;
Lee, PC ;
Lee, HS ;
Lin, PW ;
Huang, GT ;
Sheu, JC ;
Tsai, HM ;
Chau, GY ;
Chiang, JH ;
Lui, WY ;
Lee, SD ;
Wu, JC .
LIVER INTERNATIONAL, 2004, 24 (05) :419-424
[9]   Incidence and risk factors for acute renal failure in patients with hepatocellular carcinoma undergoing transarterial chemoembolization: a prospective study [J].
Huo, TI ;
Wu, JC ;
Lee, PC ;
Chang, FY ;
Lee, SD .
LIVER INTERNATIONAL, 2004, 24 (03) :210-215
[10]   Acute renal failure after transarterial chemoembolization for hepatocellular carcinoma: a retrospective study of the incidence, risk factors, clinical course and long-term outcome [J].
Huo, TI ;
Wu, JC ;
Huang, YH ;
Chiang, JH ;
Lee, PC ;
Chang, FY ;
Lee, SD .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2004, 19 (09) :999-1007